"Zepbound: Promising Treatment for Sleep Apnea and Weight Loss, Eli Lilly Reports"

Eli Lilly reported that its obesity drug tirzepatide, or Zepbound, showed promising results in reducing obstructive sleep apnea in overweight or obese individuals, with an average of about 30 fewer apnea episodes per hour. The findings from yearlong clinical trials could provide a new treatment option for the 20 million Americans diagnosed with moderate to severe obstructive sleep apnea, potentially reducing their risk for associated health issues. While the detailed results are yet to be published, experts not affiliated with the company are encouraged by the summary and look forward to more comprehensive data at the American Diabetes Association’s 84th Scientific Sessions in June.